Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo

Background Type 2 diabetics (DM2) are at increased risk for restenosis as well as nonculprit coronary artery lesion (NCCL) progression. Rosiglitazone (RSG) favorably modifies many of the altered biologic processes in DM2, although recent reports have questioned its safety. We conducted a double-blin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal 2009-02, Vol.157 (2), p.383.e1-383.e8
Hauptverfasser:	Finn, Aloke V., MD, Oh, Jae S., BS, Hendricks, Michael, BS, Daher, Maureen, RN, Cagliero, Enrico, MD, Byrne, Raphael M, Nadelson, Jeffrey, BS, Crimins, Johanna, BS, Kastrati, Adnan, MD, Schömig, Albert, MD, Bruskina, Olga, BS, Palacios, Igor, MD, John, Michael C., MPH, Gold, Herman K., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angioplasty, Balloon, Coronary Biomarkers - blood Cardiovascular Cardiovascular disease Coronary Angiography Coronary Restenosis - blood Coronary Restenosis - diagnostic imaging Coronary Restenosis - etiology Coronary Restenosis - prevention & control Coronary Stenosis - blood Coronary Stenosis - diagnostic imaging Coronary Stenosis - etiology Coronary Stenosis - prevention & control Coronary vessels Diabetes Diabetes Mellitus, Type 2 - complications Diabetic Angiopathies - complications Disease Progression Double-Blind Method Drug dosages Female Glucose Heart attacks Humans Insulin resistance Lipids Male Medical imaging Middle Aged Predictive Value of Tests Prognosis Stents Thiazolidinediones - therapeutic use Vasodilator Agents - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!